Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta

Jay Shapiro, Carol Thompson, Yimei Wu, Martin Nunes, Carolynn Gillen

Research output: Contribution to journalArticle

Abstract

The effect of bisphosphonate treatment on bone mineral density (BMD) and fracture rates was assessed in adults with osteogenesis imperfecta (OI). This observational nonrandomized study included 90 OI adults treated with intravenous pamidronate (n = 28), oral alendronate (n = 10), or oral residronate (n = 17) or not treated (n = 35). There were 63 type I, 15 type III, and 12 type IV OI patients. BMD results were observed for up to 161 months and an average of 52 months of treatment. For type I and grouped type III/IV patients, treatment with pamidronate showed an increasing rate in L1-L4 BMD from baseline (0.006 [P = 0.03] and 0.016 [P

Original languageEnglish (US)
Pages (from-to)120-129
Number of pages10
JournalCalcified Tissue International
Volume87
Issue number2
DOIs
StatePublished - 2010

Fingerprint

pamidronate
Osteogenesis Imperfecta
Bone Fractures
Diphosphonates
Bone Density
Alendronate
Observational Studies
Therapeutics

Keywords

  • Bisphosphonate
  • Bone mineral density
  • Fracture
  • Osteogenesis imperfecta
  • Pamidronate

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta. / Shapiro, Jay; Thompson, Carol; Wu, Yimei; Nunes, Martin; Gillen, Carolynn.

In: Calcified Tissue International, Vol. 87, No. 2, 2010, p. 120-129.

Research output: Contribution to journalArticle

@article{843fef07a18145dc9746413ce56d1a88,
title = "Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta",
abstract = "The effect of bisphosphonate treatment on bone mineral density (BMD) and fracture rates was assessed in adults with osteogenesis imperfecta (OI). This observational nonrandomized study included 90 OI adults treated with intravenous pamidronate (n = 28), oral alendronate (n = 10), or oral residronate (n = 17) or not treated (n = 35). There were 63 type I, 15 type III, and 12 type IV OI patients. BMD results were observed for up to 161 months and an average of 52 months of treatment. For type I and grouped type III/IV patients, treatment with pamidronate showed an increasing rate in L1-L4 BMD from baseline (0.006 [P = 0.03] and 0.016 [P",
keywords = "Bisphosphonate, Bone mineral density, Fracture, Osteogenesis imperfecta, Pamidronate",
author = "Jay Shapiro and Carol Thompson and Yimei Wu and Martin Nunes and Carolynn Gillen",
year = "2010",
doi = "10.1007/s00223-010-9383-y",
language = "English (US)",
volume = "87",
pages = "120--129",
journal = "Calcified Tissue International",
issn = "0171-967X",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta

AU - Shapiro, Jay

AU - Thompson, Carol

AU - Wu, Yimei

AU - Nunes, Martin

AU - Gillen, Carolynn

PY - 2010

Y1 - 2010

N2 - The effect of bisphosphonate treatment on bone mineral density (BMD) and fracture rates was assessed in adults with osteogenesis imperfecta (OI). This observational nonrandomized study included 90 OI adults treated with intravenous pamidronate (n = 28), oral alendronate (n = 10), or oral residronate (n = 17) or not treated (n = 35). There were 63 type I, 15 type III, and 12 type IV OI patients. BMD results were observed for up to 161 months and an average of 52 months of treatment. For type I and grouped type III/IV patients, treatment with pamidronate showed an increasing rate in L1-L4 BMD from baseline (0.006 [P = 0.03] and 0.016 [P

AB - The effect of bisphosphonate treatment on bone mineral density (BMD) and fracture rates was assessed in adults with osteogenesis imperfecta (OI). This observational nonrandomized study included 90 OI adults treated with intravenous pamidronate (n = 28), oral alendronate (n = 10), or oral residronate (n = 17) or not treated (n = 35). There were 63 type I, 15 type III, and 12 type IV OI patients. BMD results were observed for up to 161 months and an average of 52 months of treatment. For type I and grouped type III/IV patients, treatment with pamidronate showed an increasing rate in L1-L4 BMD from baseline (0.006 [P = 0.03] and 0.016 [P

KW - Bisphosphonate

KW - Bone mineral density

KW - Fracture

KW - Osteogenesis imperfecta

KW - Pamidronate

UR - http://www.scopus.com/inward/record.url?scp=79952110449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952110449&partnerID=8YFLogxK

U2 - 10.1007/s00223-010-9383-y

DO - 10.1007/s00223-010-9383-y

M3 - Article

C2 - 20544187

AN - SCOPUS:79952110449

VL - 87

SP - 120

EP - 129

JO - Calcified Tissue International

JF - Calcified Tissue International

SN - 0171-967X

IS - 2

ER -